Old Web
English
Sign In
Acemap
>
authorDetail
>
Hongguang Wang
Hongguang Wang
Peking Union Medical College
Medicine
Immunotherapy
Tyrosine kinase
Combination therapy
Oncology
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
PD-1 inhibitor combined with lenvatinib for unresectable liver cancer as the conversion therapy: An open-label, non-randomized, phase IV study.
2021
Journal of Clinical Oncology
Wenwen Zhang
Shichun Lu
Bingyang Hu
Tao Wan
Hongguang Wang
Jun Han
Ze Zhang
Junning Cao
Xianlei Xin
Yingwei Pan
Minggen Hu
Ming-Yi Chen
Yongliang Chen
Zhanyu Yang
Shou-Wang Cai
Wenbin Ji
Chenggang Li
Shuang Tong
Feilong Zhao
Xiaochen Zhao
Show All
Source
Cite
Save
Citations (0)
Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report.
2021
Frontiers in Immunology
Ze Zhang
Wenwen Zhang
Hongguang Wang
Bingyang Hu
Zhanbo Wang
Shichun Lu
Show All
Source
Cite
Save
Citations (0)
Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients.
2021
Frontiers in Oncology
Wenwen. Zhang
Bingyang Hu
Jun Han
Zhanbo Wang
Guangyu Ma
Huiyi Ye
Jing Yuan
Junning Cao
Ze Zhang
Jihang Shi
Ming-Yi Chen
Xun Wang
Yinzhe Xu
Yanshuang Cheng
Lantian Tian
Hongguang Wang
Shichun Lu
Show All
Source
Cite
Save
Citations (0)
1